
Evidence Without Access: Ph+ ALL After NEJM – A Dialogue Between Prof. Foà, Prof. Milano and Dr. Chiaretti
In this episode, Prof. Robin Foà, Prof. Filippo Milano, and Dr. Sabina Chiaretti discuss the recent publication in the New England Journal of Medicine of the first randomized phase 3 trial in frontline treatment of adult Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Accompanied by an editorial by Dr. Adele Fielding, the study marks a milestone for thedisease and for Italian cooperative research, and it has raised a clinical and regulatory paradox that the speakers explore in depth. The trial compared a chemo-free strategy, based on ponatinib followed by blinatumomab, with standard treatment with imatinib and chemotherapy. The experimental arm showed superior event-free survival and deeper molecular responses, with markedly lower toxicity. Transplant was reserved for patients with persistent measurable residual disease (MRD) or unfavorable genetics, and only 19% of patients in the experimental arm ultimately underwent it. A central theme is the gap between evidence and clinical practice. The combination of blinatumomab and a TKI in first line is not approved by EMA, AIFA, or in the United States, and compassionate use has been unsuccessful, leaving physicians bound to offer conventional treatments that the data nowshow to be inferior. The speakers also address the obstacles to future development, the role of patient advocacy organizations, and the foundations of this success within GIMEMA, which helped raise survival in Ph+ ALL from 10-15% to 80-85% over fifty years. A compelling conversation on how decades of cooperative research have redefined the treatment of Ph+ ALL, and on the responsibility to ensure that proven innovation reaches the patients who need it.